Roach JC, Glusman G, Smit AF, et al. . Science. 2010;328:636-639.
In the not-so-distant future, clinicians may order whole-genome sequencing of patient DNA the way we now order an MRI. In the run-up to the routine clinical use of whole-genome sequencing, investigators are taking advantage of this remarkable technical achievement to characterize the human genome and to solve challenging genetic and pathophysiological problems.1,2 In a recent publication in Science, the power and beauty of whole-genome sequencing was illustrated by the ingenious studies of a collaborative group of scientists led by David Galas and Leroy Hood from the Institute for Systems Biology in Seattle and Lynn Jorde from the University of Utah. The problem to be solved by the study (to identify the genetic basis of a rare autosomal recessive disorder) was straightforward, but the experimental design was inspired and the studies were made possible by the generosity and selflessness of the involved family. Roach, Glusman, Smit, and Huff, who shared first authorship on the paper, and colleagues identified a pedigree that consisted of a mother, a father, and two siblings, both of whom were affected by two distinct autosomal recessive disorders, Miller syndrome (postaxial acrofacial dysostosis) and primary ciliary dyskinesia. Sequencing the genome of the parents allowed the investigators to delineate precisely sites of recombination, and the results illustrate the remarkable genetic diversity that exists between siblings (Figure). The sibling pair was found to be only ~20 percent genetically identical, and the investigators took advantage of this finding to narrow their search for the disease-causing mutations (Figure). Reasoning that rare phenotypes would likely be encoded by rare nucleotide sequence variants allowed the investigators to further narrow the search for the disease-causing mutations. Data analysis identified sequence variants that fit the model of either simple recessive (a gene mutated at the same position in both alleles) or compound heterozygous (mutation of the same gene at different nucleotide positions in each of the two alleles) in four candidate genes. By comparing core exome sequencing of two unrelated individuals with Miller syndrome, the disease-causing mutation for Miller syndrome in the sibling pair was confirmed to be the consequence of a compound heterozygous state affecting dihydroorotate dehydrogenase (DHODH), a gene that encodes a key enzyme in pyrimidine biosynthesis. The gene (DNAH5 that encodes a dynein protein that functions as a force-generating protein with ATPase activity) that is mutated in primary ciliary dyskinesia was previously known, and the studies by Roach et al. confirmed that the gene was mutated in a compound heterozygous state in the two affected siblings. As such, primary ciliary dyskinesia served as a positive control for the studies. In the process of discovering the genetic mutation that causes Miller syndrome and confirming the genetic basis of primary ciliary dyskinesia, Roach and colleagues reported a number of other interesting, basic observations including the following: